Magnesium and Vanadium Levels in Preeclampsia

Study Overview
=================
Brief Summary
-----------------
Introduction: Vanadium important pollutants produced from anthropogenic activities, has been suggested to be embryotoxic and fetotoxic in a lot of studies. Magnesium sulfate therapy is used very common to prevent seizures in women with preeclampsia. However, the causes of preeclampsia are little known and heavy metals merit further investigation. The investigators will be tested whether late - onset preeclampsia (LOPE) was associated with exposure to these metals. Methods: This study was designed to determine maternal plasma/urine/hair magnesium and vanadium concentrations in women with LOPE (n=70) compared to those of normotensive pregnant women (n=70) and to those of normotensive-healthy non-pregnant women (n=70). These metals concentrations will be measured using inductively coupled plasma-mass spectrometry were compared.

Detailed Description
-----------------
This observational case-control study will be conducted at the Department of Obstetrics and Gynecology, Cengiz Gokcek Public Hospital, Gaziantep, Turkey, between May 2020 and February 2021. The protocol was approved by the Ethics Committee for Clinical Research of Gaziantep University (reference no: 2020/130). The study strictly will be adhered to the principles of the Declaration of Helsinki. All participants will be included in the study gave oral and written informed consent. Two-hundred ten women will be enrolled in the study in three groups.

Official Title
-----------------
Analysis of Maternal Plasma/Urine/Hair Magnesium and Vanadium Levels in Preeclampsia (PrE)

Conditions
-----------------
Preeclampsia

Intervention / Treatment
-----------------
* Other: magnesium and vanadium measurements and compare


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: preeclampsia healthy pregnancy healthy women Exclusion Criteria: pregnant women with any systemic condition (such as chronic hypertension, renal disease and diabetes mellitus) using any kind of medication/supplement intake throughout pregnancy (such as heparin) history of medication for PE treatment at the time of first admission smoking drug user patients who had fetal congenital abnormalities or genetic syndromes multiple-gestation pregnancies pregnancies resulting from in vitro fertilization intrauterine fetal death having a family history of preeclampsia Women who have menstrual irregularity Women who have dyed their hair in the last 9 months Gestational diabetes mellitus Women receiving vanadium and/or magnesium treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Preeclampsia<br>The diagnosis of LOPE, as will be defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will be established based on the presence of proteinuria and a blood pressure level of ≥140/90 mmHg that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure ≥ 160/110 mm Hg, it will be accepted as mild; and in case these values exceeded this level, it will be accepted as severe. | Other: magnesium and vanadium measurements and compare<br>* Magnesium and vanadium will be measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).<br>|
| control pregnant group<br>These participants with normal healthy pregnancies at the third trimester (before birth) | Other: magnesium and vanadium measurements and compare<br>* Magnesium and vanadium will be measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).<br>|
| control non-pregnant group<br>A volunteer group of healthy women who visited the gynaecology clinic for routine examinations and women who were admitted for pre-pregnancy tests were invited randomly to this research as a control group. | Other: magnesium and vanadium measurements and compare<br>* Magnesium and vanadium will be measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| magnesium and vanadium levels | The primary outcome in these analyses will be magnesium and vanadium levels in LOPE group and control groups. | 10 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| magnesium and vanadium levels in severy LOPE group | The secondary outcome will be compare the magnesium and vanadium levels in mild LOPE group and severy LOPE group. | 1 day |